DC Field | Value | Language |
dc.contributor.author | Costin, Patricia | - |
dc.date.accessioned | 2020-07-03T08:07:50Z | - |
dc.date.available | 2020-07-03T08:07:50Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | COSTIN, Patricia. Therapeutic options in bronchial asthma for adults. In: MedEspera: the 7th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2018, p. 280-281. | en_US |
dc.identifier.uri | https://medespera.asr.md/wp-content/uploads/Abastract-Book-2018.pdf | - |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/10881 | - |
dc.description | Department of Pharmacology
and clinical pharmacy,
Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova | en_US |
dc.description.abstract | Introduction. Bronchial asthma is one of the most common chronic diseases among children
and adults over 40 years . This illness requires complex treatment, aimed at avoiding trigger
factors, medication, physical and psychological therapy. The prevalence of this pathology in the
country is 4%, with 160 thousand asthmatics registered. The disease predominates in male
gender, with a ratio of 1.5-3 / 1. The overall prevalence of asthma varies from 1% to 18% in
different countries and the mortality rate is currently estimated between 2 and 4 cases per
100,000 population in a year.
Aim of the study. Assessment of bronchial asthma medication of the 4 stages of severity
(intermittent, persistent, moderately persistent and severely persistent) in terms of the 5 stages of
treatment.
Materials and methods. Analysis of data from the speciality literature of the last 5 years.
Results. Depending on the level of control and the evolution of the disease, the treatment of
asthma is accomplished in 5 steps. For all stages, emergency medication consists of β2 rapidacting
inhaled agonists (salbutamol nictimer dose 600-800 μg, fenoterol 600 μg) inhaled
anticholinergic drugs (ipantropium bromide 60-120 μg) and methylxanthines (300-800 μg
theophylline). At Stage 1, treatment is indicated for patients who experience symptoms of AB
less than 2 times a week. For this patient group only emergency medication is used. Step 2 is
addressed to patients with persistent asthma symptoms. In the control medication, low-dose
inhaled corticosteroids or leukotriene antagonists (montelucast 10 mg, zafirlucast 20 mg) are
recommended. Step 3 is for patients who lack control under treatment 1 and 2. For maintenance,
combinations of β2-agonists + CSI, leukotriene + CSI antagonists or theophylline retard + CSI
are recommended. Step 4 is recommended for patients who are unstable in 3rd stage treatment.
Control medication includes: Long-acting CSI + β2 agonists + small doses of retard
theophylline. Step 5 treatment is for those with severe AB. The medication is orally CS + anti-IG
E.
Conclusions. The division of the contemporary AB treatment in the 5 stages would lead to the
exclusion of overdosing and would allow a more individualized and personalized approach for
the patient. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | bronchial asthma | en_US |
dc.subject | emergency medication | en_US |
dc.subject | control medication | en_US |
dc.title | Therapeutic options in bronchial asthma for adults | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2018
|